Caplacizumab

Caplacizumab
Monoclonal antibody
Type Single domain antibody
Source Humanized
Target VWF
Identifiers
CAS Number 915810-67-2
ATC code None
ChemSpider none
Chemical data
Formula C1213H1891N357O380S10
Molar mass 27.88 kDa

Caplacizumab (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2]

This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.[3]

It is an anti-von Willebrand factor humanized immunoglobulin.[4] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[4] Results of the phase II TITAN trial have been reported.[4]

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
  2. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information 25 (4).
  3. A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
  4. 1 2 3 Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016


This article is issued from Wikipedia - version of the Friday, February 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.